Sansure Biotech Inc. (SHA:688289)

China flag China · Delayed Price · Currency is CNY
18.41
+0.07 (0.38%)
Mar 9, 2026, 3:00 PM CST
-23.70%
Market Cap 10.53B
Revenue (ttm) 1.65B
Net Income (ttm) 198.15M
Shares Out 574.18M
EPS (ttm) 0.34
PE Ratio 53.94
Forward PE 26.68
Dividend 0.54 (2.93%)
Ex-Dividend Date Sep 23, 2025
Volume 4,406,298
Average Volume 5,475,206
Open 18.13
Previous Close 18.34
Day's Range 18.04 - 18.42
52-Week Range 17.73 - 26.36
Beta 0.71
RSI 34.12
Earnings Date Apr 30, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an... [Read more]

Sector Healthcare
Founded 2008
Employees 2,409
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688289
Full Company Profile

Financial Performance

In 2025, Sansure Biotech's revenue was 1.65 billion, an increase of 13.04% compared to the previous year's 1.46 billion. Earnings were 198.15 million, a decrease of -28.10%.

Financial Statements

News

There is no news available yet.